NCT00087607View on ClinicalTrials.gov

Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).

PHASE4CompletedINTERVENTIONAL
Enrollment

385

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

March 31, 2006

Study Completion Date

April 30, 2006

Conditions
Hepatitis C, Chronic
Interventions
DRUG

Ribavirin

1000/1200mg/day po

DRUG

Peginterferon alfa-2b (PEG-Intron)

1.5 micrograms/kg sc weekly

DRUG

Ribavirin

1000/1200mg/day po

DRUG

Peginterferon alfa-2a [Pegasys]

180 micrograms sc weekly

Trial Locations (41)

10016

New York

10021

New York

10467

The Bronx

12601

Poughkeepsie

21205

Baltimore

22031

Fairfax

23502

Norfolk

24016

Roanoke

28304

Fayetteville

28677

Statesville

29204

Columbia

33125

Miami

33414

Wellington

34209

Bradenton

48201

Detroit

53405

Racine

63104

St Louis

64131

Kansas City

66160

Kansas City

68198

Omaha

70115

New Orleans

72205

Little Rock

75203

Dallas

78758

Austin

89128

Las Vegas

92103

San Diego

92123

San Diego

94143

San Francisco

94403

San Mateo

94901

San Rafael

95817

Sacramento

97239

Portland

98405

Tacoma

35295-0005

Birmingham

06030

Farmington

06015

Hartford

02215

Boston

01805

Burlington

07018

East Orange

08234

Egg Harbour Township

08360

Vineland

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00087607 - Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC). | Biotech Hunter | Biotech Hunter